Here we have demonstrated that treatment of breast cancer and colorectal cancer cells with a pan-mTOR inhibitor synergistically increases the growth-inhibitory action of the Akt-inhibitor MK2206 which corresponded with changes in the incorporation of radiolabelled choline. The gene discussed is MTOR; the disease is breast cancer.